Sabby Management’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-1,656
Closed -$2M 132
2018
Q3
$2M Buy
1,656
+220
+15% +$3.08K 0.26% 41
2018
Q2
$2.24M Buy
1,436
+436
+44% +$6.59K 0.35% 42
2018
Q1
$1.5M Sell
1,000
-1,000
-50% -$15.2K 0.18% 48
2017
Q4
$2.88M Buy
2,000
+1,500
+300% +$20.6K 0.26% 45
2017
Q3
$754K Sell
500
-2,182
-81% -$28.9K 0.05% 88
2017
Q2
$2.7M Buy
2,682
+441
+20% +$3.55K 0.18% 59
2017
Q1
$1.6M Buy
2,241
+1,101
+97% +$6.96K 0.09% 106
2016
Q4
$567K Sell
1,140
-1,142
-50% -$7.9K 0.03% 187
2016
Q3
$1.69M Buy
2,282
+48
+2% +$324 0.06% 145
2016
Q2
$1.22M Sell
2,234
-1,251
-36% -$8.75K 0.06% 144
2016
Q1
$2.94M Sell
3,485
-14
-0.4% -$99 0.15% 68
2015
Q4
$3.39M Buy
3,499
+1,177
+51% +$10.6K 0.19% 83
2015
Q3
$3.25M Buy
2,322
+1,065
+85% +$16.7K 0.13% 116
2015
Q2
$1.78M Sell
1,257
-394
-24% -$4.74K 0.06% 176
2015
Q1
$1.8M Buy
1,651
+54
+3% +$476 0.07% 156
2014
Q4
$1.33K Buy
+1,597
New +$11K 0.04% 148

Other funds holding FOLD

Sabby Management's FOLD Position: Q4 2018 in Review

Sabby Management sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 155,044 shares — an estimated $1.87M sold.

Sabby Management first reported a position in FOLD in Q2 2014 and held it in 9 quarters. The position peaked at $1.87M in Q3 2018. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Sabby Management reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sabby Management sold 155,044 Amicus Therapeutics shares in Q4 2018, an estimated $1.87M.
  • Sabby Management first reported a position in Amicus Therapeutics in Q2 2014 and held it in 9 quarters.
  • Sabby Management's Amicus Therapeutics position peaked at $1.87M in Q3 2018.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.